Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab and Secukinumab Combination in Ankylosing Spondylitis
NCT06833112Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- Feb 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab, adalimumab in ankylosing spondylitis (AS), sponsored by Affiliated Hospital of Guizhou Medical University. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
secukinumabadalimumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT06833112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06833112.